HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars
HIV Medicine Maker Theratechnologies 'Wraps Up Strong Second Quarter,' Stock Soars
On Wednesday, Theratechnologies Inc (NASDAQ:THTX) reported second-quarter 2024 sales of $22.02 million, up 25.5% year over year, beating the consensus of $21.71 million.
在週三，Theratechnologies（納斯達克股票代碼：THTX）報告稱2024年第二季度銷售額爲2202萬美元，同比增長25.5％，超過了預期的2171萬美元。
For the second quarter, net sales of EGRIFTA SV were $16.2 million, up 49.3% year over year, due to strong demand for the product, combined with weaker than usual sales in Q2 of last year stemming from drawdowns in inventory early in the second quarter of 2023.
對於第二季度，EGRIFTA SV的淨銷售額爲1620萬美元，同比增長49.3％，這是由於產品需求強勁，加上去年第二季度庫存量下降導致的銷售不如往年。庫存下降源於2023年第二季度初。
EGRIFTA SV is an injectable prescription medicine used to reduce excess abdominal fat in adults with HIV and lipodystrophy.
EGRIFTA SV是一種注射劑處方藥，用於減少艾滋病和脂肪營養不良成年人的過多腹部脂肪。
Trogarzo's net sales in the second quarter reached $5.82 million, down 13.1% year over year, primarily due to competitive pressures in the multi-drug-resistant segment of the HIV-1 market.
第二季度Trogarzo的淨銷售額達到582萬美元，同比下降13.1％，主要是由於HIV-1市場中耐多藥壓力的競爭。
Trogarzo is used in combination with other antiretroviral medicines to treat HIV‐1 infection.
Trogarzo與其他抗逆轉錄病毒藥物結合使用，用於治療HIV-1感染。
The company reported a net income of $1 million, with an adjusted EBITDA of $5.5 million.
公司報告淨利潤100萬美元，調整後的EBITDA爲550萬美元。
"EGRIFTA SV remains our priority brand, with key performance metrics showing consistent growth and continued strong gross margins. Moving forward, we expect sales to align with patient demand now that inventory levels have returned to normal. We continue to demonstrate strength on the bottom line with our fourth straight quarter of near-flat-to-positive Adjusted EBITDA. In fact, for the first time in the company's recent history, we recorded a positive net income, marking the beginning of a new and profitable journey for Theratechnologies," said Paul Lévesque, President and CEO.
“EGRIFTA SV仍然是我們的優先品牌，關鍵績效指標表現出穩定增長和持續強勁的毛利率。展望未來，我們預計銷售將與患者需求一致，現在庫存水平已恢復正常。我們在底線展現出強大的力量，已經連續四個季度實現基本持平或淨利潤爲正。實際上，公司近年來的歷史中第一次實現淨利潤爲正，標誌着Theratechnologies開啓了新的盈利之路，” Paul Lévesque, 總統兼首席執行官，說。
Theratechnologies expects that its $36.03 million cash and cash equivalents as of May 31, 2024, together with cash generated from its existing operations, will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.
Theratechnologies預計截至2024年5月31日，其3603萬美元的現金及現金等價物，加上從現有業務中產生的現金，將足以資助業務營銷費用和債務償還需求至少12個月。
Considering the recent actions, material uncertainty that raised substantial doubt about the company's ability to continue as a going concern was alleviated, effective from these second-quarter interim financial statements.
鑑於最近的行動，從這些第二季度中期財務報表開始，消除了對公司繼續作爲經營實體的實質性疑慮。
In March, the company announced that it would phase down its preclinical oncology research activities while continuing to conduct its ongoing Phase 1 trial of sudocetaxel zendusortide for advanced ovarian cancer to focus on its commercial business and generate positive Adjusted EBITDA and net income.
三月份，公司宣佈將逐步減少其臨床前腫瘤研究活動，同時繼續進行鍼對晚期卵巢癌的sudocetaxel zendusortide的第一階段試驗，以專注其商業業務，創造良好的調整後EBITDA和淨利潤。
Guidance: Theratechnologies reiterates its fiscal year 2024 revenue guidance of $87 million—$90 million, compared to the consensus of $87.88 million.
指導意見：Theratechnologies重申2024財年的營業收入指導預期爲8700萬美元至9000萬美元，與預期的8788萬美元相比。
The company anticipates 2024 adjusted EBITDA of $13 million—$15 million.
公司預計2024年調整後的EBITDA爲1300萬美元至1500萬美元。
Price Action: At last check on Wednesday, THTX shares were up 9.68% at $1.70 during the premarket session.
截至週三，THTX股票在盤前交易中上漲9.68％，價格爲1.7美元。
譯文內容由第三人軟體翻譯。